Renato D. Lopes

Sep 16, 2024 | dom-pubs.onlinelibrary.wiley.com | Hertzel C. Gerstein |Stefano Del Prato |Renato D. Lopes |Richard E. Pratley

1 BACKGROUND/CONTEXT Glucagon-like-peptide-1 receptor agonists (GLP-1 RA) lower HbA1c by promoting insulin secretion in response to elevated glucose (the incretin effect).1, 2 They also slow gastric emptying; reduce appetite, weight, blood pressure, low-density lipoprotein (LDL) cholesterol and serious health outcomes3; and increase heart rate and pancreatic enzymes. The degree to which these nonglycaemic effects mediate their glycaemic effects remains unclear.

Sep 12, 2024 | healio.com | Erik Swain |Shenaz Bagha |Renato D. Lopes

You've successfully added Arrhythmia Disorders to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Two studies found that mass screening for atrial fibrillation in older adults does not reduce stroke. In one study, levels of a biomarker may indicate who does not need to be screened.

Sep 1, 2024 | radcliffecardiology.com | Gi-Byoung Nam |Dipak Kotecha |Renato D. Lopes

ESC Congress 24 — AF screening with a wearable ECG device increases diagnosis by over 50% but did not significantly reduce hospitalisation rates for stroke.

May 19, 2024 | jacc.org | Renato D. Lopes |Christopher B Granger |Daniel Wojdyla |William F McIntyre |William Mcintyre

References1. "Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation". Ann Intern Med . 2007;146:857-867. 2. "Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials". Lancet . 2014;383:955-962. 3.

Nov 11, 2023 | jamanetwork.com | Kenneth W. Mahaffey |C. Michael Gibson |Renato D. Lopes

Systematic, standardized, and independent assessment of clinical trial end points is critical to protect the scientific integrity of clinical trials.1 Clinical event classification (CEC) has become the criterion standard for the process of event adjudication, which includes the creation of end point definitions; the identification of suspected events; the collection of information through dedicated case report forms, collection of medical records, and access to ancillary or administrative...